Express News | Xencor Announces Upcoming Change to Board of Directors
Xencor Analyst Ratings
RBC Capital Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $34
Xencor (XNCR) Gets a Buy From RBC Capital
Express News | Xencor Inc : RBC Raises Target Price to $34 From $31
Express News | Xencor Announces Proposed Public Offering of Common Stock
Unpleasant Surprises Could Be In Store For Xencor, Inc.'s (NASDAQ:XNCR) Shares
A Quick Look at Today's Ratings for Xencor(XNCR.US), With a Forecast Between $27 to $38
On Sep 10, major Wall Street analysts update their ratings for $Xencor(XNCR.US)$, with price targets ranging from $27 to $38.J.P. Morgan analyst Brian Cheng maintains with a buy rating, and adjusts
Small U.S. Stocks Finish Mixed As Xencor Lead, Tango Therapeutics Lags
Sector Update: Health Care Stocks Rise Monday Afternoon
Xencor Up 25%, on Pace for Largest Percent Increase Since March 2020 -- Data Talk
50 Stocks That May See Selling Pressure as Investors Begin Looking to Book Tax Losses
Xencor Announces XmAb Drug Candidates in Autoimmune Disease With Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
Zenas BioPharma, Bicara Therapeutics Sets IPO Price Ranges as Summer Lull Ends
Zenas BioPharma Sets Price Range for $200 Million Initial Public Offering
Express News | Zenas Biopharma Inc Says Bristol-Myers Squibb Co, Xencor Inc Are Among 5% or Greater Stockholders in the Company
Leerink Partners Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $32
Leerink Partners analyst Jonathan Chang maintains $Xencor(XNCR.US)$ with a buy rating, and adjusts the target price from $29 to $32.According to TipRanks data, the analyst has a success rate of 33.1%
Buy Rating Affirmed for Xencor on Promising XmAb819 Developments and Strong Strategic Position
Express News | Xencor Inc : Leerink Partners Raises Target Price to $32 From $29